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Abstract
Although tumor size and lymph node involvement are the current cornerstones of breast cancer prognosis, they have not
been extensively explored in relation to tumor methylation attributes in conjunction with other tumor and patient dietary
and hormonal characteristics. Using primary breast tumors from 162 (AJCC stage I–IV) women from the Kaiser Division of
Research Pathways Study and the Illumina GoldenGate methylation bead-array platform, we measured 1,413 autosomal
CpG loci associated with 773 cancer-related genes and validated select CpG loci with Sequenom EpiTYPER. Tumor grade,
size, estrogen and progesterone receptor status, and triple negative status were significantly (Q-values ,0.05) associated
with altered methylation of 209, 74, 183, 69, and 130 loci, respectively. Unsupervised clustering, using a recursively
partitioned mixture model (RPMM), of all autosomal CpG loci revealed eight distinct methylation classes. Methylation class
membership was significantly associated with patient race (P,0.02) and tumor size (P,0.001) in univariate tests. Using
multinomial logistic regression to adjust for potential confounders, patient age and tumor size, as well as known disease risk
factors of alcohol intake and total dietary folate, were all significantly (P,0.0001) associated with methylation class
membership. Breast cancer prognostic characteristics and risk-related exposures appear to be associated with gene-specific
tumor methylation, as well as overall methylation patterns.
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Introduction
Breast cancer is the most common non-skin cancer among
American women. The American Cancer Society’s estimates
indicate approximately 1.3 million new cases of invasive breast
cancer were diagnosed globally in 2007; and nearly 500,000
women died from the disease [1]. Currently, there are over 2.5
million breast cancer survivors in the US, and an estimated $8.1
billion dollars is spent each year on treatment of breast cancer [2].
The principal prognostic indicator currently in clinical use for
breast cancer is the tumor-node-metastasis (TNM) stage [3,4].
Morphological attributes of malignant tumors that influence
disease prognosis are the size of the primary tumor (T), presence
and extent of regional lymph node involvement (N) and presence
of distant metastases (M). Molecular attributes of tumors are also
considered in clinical decision-making; loss of hormone receptor
expression [5] and increased expression of ERBB2 [6] have each
been associated with poor prognosis. Although numerous recent
studies have demonstrated that alterations of DNA methylation
in breast cancers are common and may be important etiologic
and prognostic markers [7-14], large gaps in our knowledge
remain. There is a notable lack of studies examining tumor DNA
methylation in relation to breast cancer risk factors such as diet
or reproductive factors in conjunction with other important
tumor markers. Patient exposures such as alcohol and folate
intake have potentially strong mechanistic links to epigenetic
dysregulation [15]. In addition, recent work in-vitro and in
animal models suggest that long term exposure to estrogen may
lead to epigenetic effects and altered profiles of DNA
methylation [16,17]. To explore associations of tumor methyl-
ation with important tumor and patient characteristics, we
analyzed tumors from breast cancer patients in the Kaiser
Permanente Division of Research Pathways Study using a large
scale methylation array.
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Unsupervised clustering and locus-by-locus analysis
Table 1 shows the patient demographic, hormonal, dietary and
tumor characteristics for the 162 women overall (and stratified by
menopausal status in Table S1). Results of unsupervised
hierarchical clustering of the 750 most variable CpG loci indicate
the epigenetic heterogeneity of these tumors (Figure 1).
In array-wide locus-by-locus analysis the strongest associations
of methylation of individual loci (Q-values ,0.05) were observed
for tumor grade (loci n=209), tumor size (loci n=74), estrogen
receptor status (loci n=183), progesterone receptor status (loci
n=69), and triple negative status (tumors negative for both
estrogen and progesterone receptors as well as ERBB2; loci
n=130; Table S2). Together with tumor size, patient lymph node
status is used in tumor staging. Among five CpG loci whose
methylation was significantly associated (Q,0.05) with lymph
node status, four (two in COL1A2, and one each in LOX and
P2RX7) were also associated with tumor size (Q,0.05). Addition-
ally, there was a trend of increased methylation associated with
increased tumor size: for all 74 CpG loci that were significantly
associated with tumor size (Q,0.05) methylation increased with
larger tumor size. Similarly, all five CpGs associated with disease-
positive lymph nodes had increased methylation in tumors in
women with disease-positive lymph nodes. Details of locus-by-
locus analyses for tumor grade, size, hormone receptor, and triple
negative status (loci with Q,0.05) are given in Table S3.
Array validation
Methylation array validation was performed at CpGs with
highly ranked associations from locus-by-locus analysis. The array
CpG whose methylation was most significantly increased with
increasing tumor stage was in the FES gene (Table S3) and array
methylation was significantly correlated with Sequenom methyl-
ation (rho=0.68, P=1.1E-12, n=85; Figure 2A). Promoter CpGs
in P2RX7 and HSD17B12 had significantly increased methylation
(Q,0.0001, and Q=0.01 respectively) with increasing tumor size
(Table S3) and array methylation at these CpGs were significantly
correlated with Sequenom methylation (P2RX7; rho=0.65,
P=8.6E-12, n=88; HSD17B12; rho=0.34, P=5.4E-05,
n=137; Figure 2B and 2C). A promoter CpG in GSTM2 had
significantly increased methylation with increasing tumor grade
Table 1. Patient demographic, hormonal, dietary, and tumor
characteristics.
All cases
Covariate n=162 missing
Age Range (median) 30–91 1
Median 59
Mean (sd) 59.2 (11.6)
Race Caucasian, n (%) 117 (72.7) 1
African American 13 (8.1)
Hispanic 10 (6.2)
Asian 10 (6.2)
Other 11 (6.8)
Alcohol (g/day) Range (median) 0–83.2 (1.8) 8
Mean (sd) 9.1 (15.4)
Dietary folate (ug/day) Range (median) 43.5–1610 (427) 7
Mean (sd) 459 (213)
Body mass index Range (median) 18.5–56.1 (27.4) 2
Mean (sd) 29.0 (6.7)
Parity Nulliparous, n (%) 30 (18.8) 2
1–2 children 77 (48.1)
3–4 children 45 (28.1)
5+ children 8 (5.0)
Histology Ductal, n (%) 94 (59.1) 3
Lobular 56 (35.2)
Adenocarcinoma 9 (5.7)
Estrogen receptor Positive, n (%) 141 (87.6) 1
Negative 20 (12.4)
Progesterone receptor Positive, n (%) 119 (73.4) 1
Negative 42 (26.6)
ERBB2 Negative, n (%) 134 (85.9) 3
Positive 22 (14.1)
Triple negative No, n (%) 145 (91.2) 3
Yes 14 (8.8)
AJCC stage I, n (%) 95 (59.0) 1
II 47 (29.2)
III 15 (9.3)
IV 4 (2.5)
Tumor Grade Well differentiated, n (%) 48 (30.0)
Moderately differentiated 79 (49.4) 2
Poorly differentiated 32 (20.0)
Undifferentiated 1 (0.6)
Lymph node status Positive, n (%) 48 (30.8) 6
Negative 108 (69.2)
Tumor Size (mm) Range (median) 0–135 (14.0) 0
Mean (sd) 17.4 (15.0)
doi:10.1371/journal.pgen.1001043.t001
Author Summary
The current standard prognostic indicator for breast cancer
is tumor-node-metastasis staging; though, as population-
based studies and clinical trials are conducted, molecular
characterization of disease is beginning to allow improved
markers of prognosis and assist clinicians in choosing the
most appropriate therapies. We investigated DNA meth-
ylation profiles in over 160 well annotated breast tumor
samples and found significant relationships with standard
and other known predictors of prognosis, as well as
established risk factors for disease: alcohol intake and
dietary folate. Recently the United States National Cancer
Institute Cancer Biomarkers Research Group articulated a
need for a ‘‘Strategic Approach to Validating Methylated
Genes as Biomarkers for Breast Cancer,’’ and our work is
extremely responsive to this call for a national strategy.
Recognizing the increasing use of pre-operative chemo-
therapy for patients with operable, early-stage disease,
there is added complexity in breast cancer staging. Since
chemotherapy can considerably decrease tumor size, it is
still unclear whether pre-operative or post-operative stage
best informs prognosis and treatment decisions for
patients electing pre-operative chemotherapy. However,
our data clearly illustrate the promise of tumor DNA
methylation for augmenting tumor staging and can be
attained with minimal tissue in a pre-operative context.
Breast Tumor DNA Methylation Profiles
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Sequenom methylation (rho=0.83, P,2.2E-16, n=140;
Figure 2D). Additionally, in all cases, Sequenom methylation
values were significantly associated with respective covariates;
tumor stage with FES methylation (P=0.05), tumor size with
P2RX7 (P,0.005) and HSD17B12 methylation (P,0.02), and
tumor grade with GSTM2 methylation (P,0.001). Furthermore,
relative mRNA expression of GSTM2 was significantly decreased
among tumors with high array methylation at both CpGs
associated with tumor grade (P,0.001 and P,0.03, Figure S1).
Clustering of DNA methylation patterns with RPMM
In order to explore overall methylation profiles of these tumors
and their potential relationships with patient demographic, tumor
and exposure characteristics we applied a modified model-based
form of unsupervised clustering known as recursively partitioned
mixture modeling (RPMM) [18]. The RPMM resulted in the eight
methylation classes (average methylation profiles shown in
Figure 3). Patient race was significantly associated with methyl-
ation class membership (P=0.015, Table 2), with the majority of
African Americans (54%) residing in class 2, and 40% of Hispanic
cases residing in class 4. An association between methylation class
membership and alcohol consumption approached statistical
significance (P=0.07, ever vs. never drinker, Table 2). Both
supplemental folic acid intake (mg/day) and total dietary folate
(mg/day) had associations with methylation class membership that
approached statistical significance (P=0.06 and P=0.08 respec-
tively; Table 2). For both folate variables, cases in methylation
class 4 had the lowest intake and cases in methylation class 6 had
the highest intake. Of the tumor characteristic variables, only
tumor size was significantly associated with overall methylation
profile (P=0.0006, Table 2).
Figure 2. Array methylation is validated by Sequenom EpiTYPER. Results from GoldenGate array methylation values are plotted versus
Sequenom EpiTYPER quantitative methylation values. (A) Sequenom FES methylation is significantly correlated with GoldenGate methylation average
b at the coordinate array CpG (Spearman correlation rho=0.68, P=1.1E-12, n=85). (B) Sequenom P2RX7 methylation is significantly correlated with
GoldenGate methylation average b at the coordinate array CpG (rho=0.65, P=8.6E-12, n=88). (C) Sequenom HSD17B12 methylation is significantly
correlated with GoldenGate methylation average b at the coordinate array CpG (rho=0.34, P=5.4E-05, n=137). (D) Sequenom GSTM2 methylation is
significantly correlated with GoldenGate methylation average b at the coordinate array CpG (rho=0.83, P,2.2E-16, n=140).
doi:10.1371/journal.pgen.1001043.g002
Figure 1. Unsupervised clustering heatmap of CpG methyla-
tion in breast carcinomas. Unsupervised hierarchical clustering heat
map based on Manhattan distance and average linkage of the 750
autosomal CpG loci with the highest variance. Samples are in rows
(n=162), and CpG loci are in columns. Blue indicates methylated and
yellow indicates unmethylated.
doi:10.1371/journal.pgen.1001043.g001
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intake
Associations between alcohol intake and dietary folate and
methylation class membership approached statistical significance.
While methylation of only one CpG locus (in IL17RB) was
significantly associated with folate intake in locus-by-locus tests
(Q,0.05), regression coefficients from univariate locus-by-locus
analysis plotted against their respective P-values revealed trends in
the pattern of methylation for both alcohol and folate intake.
Figure 4A illustrates the strong trend for patients with increasing
alcohol intake to have negative regression coefficients, indicative of
decreased methylation. In contrast, the trend for patients with
increasing total dietary folate shows a strong shift to positive
regression coefficients, indicative of increased methylation
(Figure 4B).
Multivariate modeling of RPMM classes
The relationships between methylation classes and several
covariates of interest were then modeled together using multino-
mial logistic regression in order to adjust for other factors in the
model. Patient age, alcohol consumption, total dietary folate, and
tumor size were each strongly associated with methylation class
membership when controlling for all modeled variables (all Wald
P-values ,0.0001) and complete model details are given in Table
S4. Figure 5 displays an illustration of the model results for
covariates significantly associated with methylation classes. As
alcohol consumption increased, there was an increased probability
of cases residing in methylation classes 3 and 8, and a concomitant
decrease in the probability of cases residing in classes 2 and 4
(Figure 5B). Increasing total dietary folate intake imparted a
striking increase in the probability of membership in class 6, and a
decreased probability of class membership in classes 1, 3, 4, and 7
(Figure 5C). The strong association between tumor size and
methylation class membership remained after controlling for
potential confounders, with the probability of patients being in
class 2 increasing from about 20% to about 60% across the span of
tumor size from 0 mm to 80+mm (Figure 5D). Accompanying this
trend for tumor size were simultaneous decreases in the probability
of cases with increasingly large tumors residing in classes 1 and 5–
8, while tumor size had less influence on the probability for
residing in classes 3 or 4 (Figure 5D).
Hormone receptor status among postmenopausal cases
Although neither estrogen nor progesterone receptor status
were significantly associated with RPMM methylation profiles,
large numbers of specific CpG loci had significant methylation
associations with these tumor characteristics in locus-by-locus
analysis (Table S2 and Table S3). Compared to the overall
population of women diagnosed with breast cancer in the Kiaser
Permanente Northern California cancer registry from 200–2009,
this surgical cohort has a higher prevalence of hormone receptor
positivity (78% overall vs. 88% here), particularly among pre-
menopausal women’s tumors (74% overall vs. 95% here). We
therefore stratified on menopausal status, running RPMM on
methylation data from post menopausal patients’ tumors only
(n=117). This model resulted in eleven methylation classes (Figure
S2) and methylation class membership was significantly associated
with estrogen receptor status (P,0.03), and the association for
triple negative tumors approached significance (P=0.07) detailed
results available in Table S5.
Discussion
It is becoming increasingly common to include data on
molecular alterations from patient tumor samples into routine
clinical practice as a means of improving prognosis and evaluating
the predictive power of alterations of interest. As technology
improves and population-based studies and clinical trials are
conducted, medicine is being ushered into a new era of molecular
characterization of disease. Tumor-node-metastasis (TNM) stage is
the current prognostic indicator for breast cancer, though several
clinical trials are currently under way to investigate the utility of
molecular markers [19], and as more patients elect neoadjuvant
therapy (specifically pre-operative chemotherapy), improved
clinical staging and additional staging tools are poised to have
great impact. Most current studies and one commercially available
tool (Oncotype DX) are focused on gene expression markers,
though the inherent instability of mRNA may make implemen-
tation of these strategies challenging outside of major surgical
centers or centralized commercial laboratories. In contrast, DNA
methylation is a stable mechanism of control of transcription, and
the stability of DNA makes it an attractive target for accurate and
reproducible assessment. Here we reported that tumor size, a
cornerstone of breast cancer prognosis, is associated with tumor
DNA methylation profile. In addition, we found that alcohol and
folate intake, exposures related to disease risk, are independently
associated with tumor DNA methylation profiles. This work sheds
light on the relationship between important etiologic exposures
Figure 3. Recursively partitioned mixture model of CpG
methylation in breast carcinomas. The figure depicts the results
of RPMM. Columns represent CpG sites and rows represent methylation
classes. The height of each row is proportional to the number of
observations residing in the class, total n=162. Blue indicates
methylated and yellow indicates unmethylated. Methylation classes
are numbered one through eight on the left. The color of the columns
within each class represents the average methylation of the CpG for
that class.
doi:10.1371/journal.pgen.1001043.g003
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utility of molecular characterization in tumor staging, and can be
accomplished with minimal tissue in a pre-operative context.
The recently updated American Joint Committee on Cancer
(AJCC) staging manual for breast cancer does not include
additional molecular markers, though the committee acknowl-
edged their consideration of markers such as hormone receptor
status and stated that TNM staging ‘‘may play increasingly less
important roles than understanding the biology of the cancer’’
[4]. Examining TNM variables we found that overall DNA
methylation profile and methylation alterations in dozens of
individual CpG loci were significantly associated with tumor size
(all increased methylation). In contrast, methylation alterations of
only five CpG loci (two in COL1A2, and one each in FAS, LOX,
and P2RX7) were significantly associated with disease-positive
lymph nodes. However, methylation of four of five lymph-node-
positive associated CpGs (excepting FAS) were also significantly
associated with tumor size, suggesting that these phenotypes are
mechanistically related, and at least in part manifest via
epigenetic alterations. As FAS encodes a TNF-receptor involved
in regulating apoptosis it is not surprising that methylation-
induced silencing of this receptor is associated with disease-
positive lymph node status. In addition, hypermethylation of
COL1A2 (collagen type I, alpha 2) has been associated with both
proliferation and migration activity in bladder cancer [20], LOX
Table 2. RPMM methylation calss membership by patient demographic and tumor characteristic covariates.
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 Class 7 Class 8 Permutation
Covariate n=68 n=39 n=23 n=14 n=5 n=4 n=4 n=5 test P*
Age (years) Mean (sd) 60.8 (11.7) 56.6 (10.4) 61.3 (13.4) 61.4 (10.2) 61.0 (9.0) 57.5 (15.5) 53.8 (10.8) 49.6 (8.0) 0.23
Race Caucasian, n (%) 53 (79.1) 29 (74.4) 17 (73.9) 7 (50.0) 3 (60.0) 3 (75.0) 2 (50.0) 3 (60.0) 0.015
Hispanic 6 (9.0) 0 2 (7.4) 0 0 1 (25.0) 0 1 (20.0)
African American 1 (1.5) 7 (18.0) 2 (7.4) 2 (14.3) 0 0 1 (25.0) 0
Asian 3 (4.5) 3 (7.7) 0 4 (28.6) 0 0 0 0
Other 4 (6.0) 0 2 (7.4) 1 (7.1) 2 (40.0) 1 (25.0) 1 (25.0) 1 (20.0)
Alcohol Never drinker, n (%)16 (24.6) 13 (36.1) 6 (27.2) 6 (42.9) 0 (0) 3 (75.0) 0 (0) 0 (0) 0.07
Ever drinker 49 (75.4) 23 (63.9) 16 (72.7) 8 (57.1) 5 (100) 1 (25.0) 4 (100) 5 (100)
Alcohol (g/day) Mean (sd) 10.2 (16.5) 6.3 (10.0) 11.4 (16.0) 2.3 (4.5) 6.8 (4.0) 8.9 (17.8) 9.1 (11.9) 27.9 (37.9) 0.27
Folic acid (ı `g/day) Mean (sd) 90.2 (68.8) 118 (133) 91.1 (60.2) 55.6 (30.6) 92.9 (37.5) 159 (7.1) 97.7 (52.8) 100 (44.6) 0.06
Dietary folate (ı `g/day) Mean (sd) 457 (209) 497 (284) 405 (145) 378 (138) 522 (114) 648 (109) 386 (145) 538 (170) 0.08
Stage Low (1 or 2), n (%) 44 (65.7) 16 (41.0) 12 (52.1) 10 (71.4) 4 (80.0) 2 (50.0) 3 (75.0) 4 (80.0) 0.18
High (3 or 4) 23 (44.3) 23 (59.0) 11 (47.9) 4 (28.6) 1 (20.0) 2 (50.0) 1 (25.0) 1 (20.0)
Lymph Node status Negative 48 (73.8) 22 (57.9) 12 (54.5) 10 (76.9) 5 (100) 4 (100) 3 (75) 4 (80) 0.19
Positive 17 (26.2) 16 (42.1) 10 (45.5) 2 (23.1) 0 0 1 (25) 1 (20)
Tumor Size (mm) Mean (sd) 14.7 (8.9) 24.2 (21.5) 18.3 (12.7) 18.0 (20.0) 13.0 (12.6) 15.3 (13.0) 8.5 (4.9) 9 (9.2) 0.0006
Estrogen receptor Positive, n (%) 60 (89.6) 35 (89.7) 19 (82.6) 11 (78.6) 4 (80.0) 4 (100) 3 (75.0) 5 (100) 0.75
Negative 7 (10.4) 4 (10.3) 4 (17.4) 3 (21.4) 1 (20.0) 0 1 (25.0) 0
Parity Nulliparous, n (%) 13 (19.4) 7 (17.9) 3 (13.6) 2 (14.3) 1 (20.0) 1 (25.0) 1 (25.0) 2 (40.0) 0.95
1–2 children 29 (43.3) 20 (51.3) 13 (59.1) 5 (35.7) 3 (60.0) 1 (25.0) 3 (75.0) 3 (60.0)
3–4 children 22 (32.8) 9 (23.1) 5 (22.7) 6 (42.9) 1 (20.0) 2 (50.0) 0 0
$5 children 3 (4.5) 3 (7.7) 1 (4.5) 1 (7.1) 0 0 0 0
Oral contraceptive No, n (%) 21 (31.3) 5 (13.5) 7 (31.8) 6 (42.9) 1 (20.0) 1 (25.0) 0 1 (20.0) 0.35
Yes 46 (68.7) 32 (86.5) 15 (62.2) 8 (57.1) 4 (80.0) 3 (75.0) 4 (100) 4 (80.0)
*Running 10,000 permutations.
Tumor grade, histology, and menopausal status were not significantly associated with methylation class.
doi:10.1371/journal.pgen.1001043.t002
Figure 4. There is an opposite trend for direction of association
between breast carcinoma CpG methylation and alcohol intake
compared to folate intake. P-values for alcohol intake (g/day) and
total dietary folate (mg/day) are plotted versus regression coefficients
from locus-by-locus analysis of CpG methylation. Horizontal blue dotted
line intercepts the y-axis at 0.05 to illustrate significance (before
correction for multiple comparisons). The vertical solid black like
intercepts the x-axis at zero to illustrate the contrasting trends. (A)
There is a trend toward decreased methylation with increasing alcohol
intake. (B) There is a trend toward increased methylation with
increasing dietary folate.
doi:10.1371/journal.pgen.1001043.g004
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P2RX7 loss has been linked to morphologic changes in stroma
related to altered collagen fibril alignment [22]. Collectively these
data suggest that perturbations in collagen and collagen-related
genes promote tumor growth and invasion, perhaps by altering
the architecture of connective tissues in the tumor microenviron-
ment. In support of this hypothesis, recent work in a mouse
model has shown that altered mammary stromal tissue collagen
expression significantly increases tumor formation and invasive-
ness potential [23]. Additionally, Chernov et al. showned that
epigenetic alterations in collagen and collagen-related genes
allows the deposition of an invasion-promoting collagen matrix in
both breast and brain tumor cell lines [24].
The primary objective of TNM staging is to provide a standard
prognosis nomenclature for patient care [4], and our results
suggest that methylation markers may be a robust proxy for tumor
size. Importantly, broader application of neoadjuvant therapy
complicates breast cancer staging since chemotherapy can
considerably decrease tumor size prior to surgical treatment, and
it is still unclear whether clinical or pathologic stage best informs
prognosis and treatment decisions [19]. The AJCC has added
methodology (yc or ypTNM) for differentiating clinical and
pathologic staging; in part, this is from recognition of the
increasing use of neoadjuvant therapy for patients with operable,
early stage disease [4,25,26]. Our data illustrate the promise of
tumor DNA methylation for augmenting tumor staging. However,
additional study of the relationship between tumor methylation
and size in both pretreatment and postoperative samples is
necessary. Specifically, the value of methylation to act as an
additional marker of size in the neoadjuvant setting should be
evaluated in future studies that compare both imaging and
pathologically based size determination.
Figure 5. Probability of methylation class membership is significantly associated with tumor size, patient age, alcohol intake, and
dietary folate when controlling for potential confounders in a multinomial logistic regression model. Results from a multinomial
logistic regression plot the probability of methylation class membership versus covariates controlled for age, race, alcohol consumption, total dietary
folate, tumor stage (low vs. high), tumor grade, tumor size, estrogen receptor status, and histology. The referent class (methylation class 3) is on the
bottom of the plot in blue-green, remaining classes are plotted in numeric order from bottom to top as shown in the legend. (A) Patient age is
significantly associated with methylation class membership (Overall Wald P,0.0001), and all methylation classes except class 4 are individually
significantly associated with patient age. (B) Alcohol consumption is significantly associated with methylation class membership (Wald P,0.0001),
and methylation classes 2, 4, 5, and 8 are individually significantly associated with alcohol intake. (C) !Total dietary folate intake is significantly
associated with methylation class membership (Wald P,0.0001), and all methylation classes are individually significantly associated with total dietary
folate. (D) Tumor size is significantly associated with methylation class membership (Wald P,0.0001), and all methylation classes except class 4 are
individually significantly associated with tumor size.
doi:10.1371/journal.pgen.1001043.g005
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profiles and individual loci for disease prognosis and recurrence,
these patients continue to be followed for these events.
Associations between DNA methylation and patient survival have
been reported for individual genes such as GSTP1 and PITX
[7,8,10], though overall DNA methylation profiles, or patterns of
methylation at selected CpG loci or genes, may improve predictive
power. Well recognized molecular subtypes of breast cancer such
as hormone receptor negative and ERBB2 over-expressing tumors
are known to be associated with reduced survival [27], and it will
be necessary to extensively examine methylation markers stratified
by commonly used molecular tumor markers. However, we did
not find significant associations between ERBB2 status and CpG
methylation in our analysis. Nonetheless, other well recognized
molecular subtype markers; estrogen receptor, progesterone
receptor, and triple negative status were among the covariates
with the highest number of significant CpGs from array-wide
locus-by-locus analysis. However, hormone receptor status and
triple negativity were not associated with methylation profile when
modeling all cases. Premenopausal patients’ tumors in our surgical
cohort had a higher prevalence of hormone receptor positivity
compared to the overall population of premenopausal patients
diagnosed with breast cancer. In order to address the potential bias
this introduced we modeled the methylation profiles of postmen-
opausal patients’ tumors separately and found a significant
association between estrogen receptor status and methylation
class. Additional study will be needed to better understand the role
of hormone receptor and growth factor receptor expression in
these tumors as they relate to methylation profile in the context of
a patient’s menopausal status.
We found significant, independent associations between both
alcohol and folate intake and overall tumor DNA methylation
profiles when controlling for potential confounders. Folate is a B
vitamin that donates its methyl group for homocysteine remethy-
lation to methionine as part of one-carbon metabolism. In turn,
methionine is the methyl donor for DNA methylation via S-
adenosyl methionine. However, alcohol is known to interfere with
folate absorption in the intestine and hepatic release of folate, and
hence, supply to tissues [28]. In fact, strong evidence of an
etiologic role for alcohol in breast cancer has been reported in
multiple meta-analyses of prospective and case-control studies with
an excess risk for each alcoholic drink per day of about 10%
[29,30]. In contrast, meta-analysis of prospective studies has not
provided clear support for an overall protective association
between folate intake and breast cancer risk [31]. Yet, meta-
analysis of case control studies of dietary folate, including results
from the Shanghai Breast Cancer Study (whose participants are
not regular alcohol drinkers) generally support a protective role for
folate [31,32].
While there have been numerous studies of alcohol and folate in
relation to risk of breast cancer, investigations of the relationship
between these exposures and epigenetic alterations in tumors
themselves are scarce. Tao et al. reported that the prevalence of
breast tumor methylation at CDKN2A, CDH1, and RARB did not
differ by folate intake or lifetime alcohol consumption in genotype
strata of one-carbon metabolism enzymes methylenetetrahydrofo-
late reductase (MTHFR) and methionine synthase (MTR) [33].
Consistent with these findings (and perhaps the lack of similar null
results in the literature), we too did not find associations between
alcohol or folate and methylation of CpG loci in CDKN2A, CDH1,
and RARB. Further, after correcting for multiple comparisons, no
CpG loci had significant alcohol-related methylation, and only one
CpG locus (in the IL17RB promoter) was associated with folate
intake. Alone, these results suggested that folate and alcohol intake
do not influence tumor DNA methylation. However, plots of
regression coefficients indicated strong independent trends for
increased folate and reduced alcohol intake associations with
increased CpG methylation. Since global, low-level effects of
alcohol and folate intake on CpG methylation may not be
detectable at individual CpGs in a genome-wide context, we
examined the global relationships between alcohol or folate intake
and DNA methylation using RPMM methylation classes.
Modeling both exposures together revealed highly significant,
independent associations between alcohol and folate and DNA
methylation profile. Another human cancer for which alcohol is an
important etiologic factor is head and neck squamous cell
carcinoma, and previous work from our group demonstrated a
similar relationship between DNA methylation profiles of these
tumors and alcohol consumption [34]. Taken together with the
weak mutagenic potential of alcohol [35], these results suggest that
a major carcinogenic mechanism of action of alcohol is
interference with epigenetic regulation through disruption of
one-carbon metabolism.
In summary, we found tumor DNA methylation associated with
tumor characteristics predictive of prognosis, and DNA methyl-
ation and patient exposures known to be related to disease risk.
Additional study is needed to determine the prognostic value of
DNA methylation markers. However, the potential clinical utility
of tumor-size-related DNA methylation is apparent.
Materials and Methods
Study population
The Pathways Study is a prospective cohort study of breast
cancer survival actively recruiting women diagnosed with invasive
breast cancer from the Kaiser Permanente Northern California
(KPNC) patient population since January 2006. Further study
details are provided elsewhere [36]. Written informed consent is
obtained from all participants before they are enrolled in the study.
The study was approved by the IRB of KPNC and all
collaborating sites.
Demographic, hormonal, and dietary factors
During the in-person baseline interview, participants were asked
detailed information on family history of cancer and reproductive
history, including: age at first full-term pregnancy, number of
biological children, breastfeeding, and menopausal status. Addi-
tional information was collected on smoking, alcohol use, hormone
use (oral contraceptives, hormone replacement therapy), and
demographics (age at breast cancer diagnosis, race/ethnicity,
household income, education). Self-reported height and weight
around diagnosis was obtained to calculate body mass index (BMI,
kg/m
2). Any missing values were supplemented by concurrent
information from KPNC electronic medical records.
Tumor characteristics
Data on estrogen and progesterone receptor status and ERBB2
expression were obtained from the KPNC Cancer Registry [37].
Tumor size was measured in a uniform manner by participating
study pathologists. Data are collected, coded, and added to the
KPNC registry approximately four months post-diagnosis to allow
for the completion of treatment. For all breast surgical specimens,
hormone receptor status and ERBB2 expression is routinely
determined by IHC at the KPNC regional IHC lab, and if the
IHC staining for ERBB2 expression is equivocal (less than 30%
strong staining, but more than 10% weak staining), by fluorescence
in situ hybridization at the KPNC regional cytogenetics lab.
Breast Tumor DNA Methylation Profiles
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162 tumor specimens from the initial diagnostic biopsy were
obtained from the KPNC tumor biorepository for methylation
analysis. All tumor specimens were from patients who did not
receive neoadjuvant chemotherapy.
Methylation analysis
FFPE tissue DNA was extracted using the QIAamp DNA mini
kit according to the manufacturer’s protocol (Qiagen, Valencia,
CA). DNA was treated with sodium bisulfite to convert
unmethylated cytosines to uracil using the EZ DNA Methylation
Kit (Zymo Research, Orange, CA) according to the manufactur-
er’s protocol. Illumina GoldenGate methylation bead arrays were
used to simultaneously interrogate 1505 CpG loci associated with
803 cancer-related genes. Bead arrays have a similar sensitivity as
quantitative methylation-specific PCR and were run at the UCSF
Institute for Human Genetics, Genomics Core Facility according
to the manufacturer’s protocol and as described by Bibikova et al
[38]. GoldenGate array methylation data are publicly available on
the Gene Expression Omnibus archive, accession GSE22290.
Array methylation validation by Sequenom EpiTYPER
mass spectroscopy
Array methylation was validated with Sequenom EpiTYPER
base-specific cleavage and MALDI-TOF MS of bisulfite treated
DNA [39]. EpiTYPER assays were designed for CpG loci both
with significant associations between methylation and tumor
characteristic variables as well as a high standard deviation of
methylation values across samples. One assay (for COL1A2) failed
the design process. Samples were processed at the UCSF Institute
for Human Genetics, Genomics Core Facility. Briefly, PCR with
primers located on either side of the CpG sites of interest are
transcribed into an RNA transcript and cleaved base specifically.
The cleavage products are analyzed by MALDI-TOF MS, and a
characteristic mass signal pattern that distinguishes methyl-
cytosine from thymine is obtained.
Gene expression by RT–PCR
Messenger RNA expression was measured using RT-PCR with
preamplification using a validated approach [40]. RNA extraction
was performed using the RecoverAll (Ambion), with a 16 hour
tissue digestion and yields were determined using a Nanodrop
spectrophotometer. Samples were concentration-normalized and
reverse-transcribed with iScript cDNA synthesis kit (BioRad).
Following cDNA synthesis, we performed linear, gene specific
preamplification of samples and controls using the TaqMan
preamp protocol (Applied Biosystems). Relative expression was
measured using a HT7900 real time PCR instrument (Applied
Biosystems).
Statistical analysis
Data assembly. Data were assembled with BeadStudio
methylation software from Illumina (SanDiego, CA). All array
data points are represented by fluorescent signals from both
methylated (Cy5) and unmethylated (Cy3) alleles, and methylation
level is given by b=(max(Cy5, 0))/(|Cy3|+|Cy5|+100), the
average methylation (b) value is derived from the ,30 replicate
methylation measurements. Raw average b values were analyzed
without normalization as recommended by Illumina. At each locus
for each sample the detection P-value was used to determine
sample performance; all samples, had detection P-values ,1e-5 at
more than 75% of CpG loci and passed performance criteria.
CpG loci with a median detection P-value .0.05 (n=8, 0.5%),
were eliminated from analysis. All CpG loci on the X chromosome
were excluded from analysis. The final dataset contained 1413
CpG loci associated with 773 genes.
Unsupervised clustering. Subsequent analyses were carried
out using the R software [41]. For exploratory and visualization
purposes, hierarchical clustering was performed using R function
hclust with Manhattan metric and average linkage. To discern and
describe the relationships between CpG methylation and patient
and tumor covariates a modified model-based form of
unsupervised clustering known as recursively partitioned mixture
modeling (RPMM) was used as described in [18] and as used in
[42]. Permutation tests (running 10,000 permutations) were used
to test for association with methylation class by generating a
distribution of the test statistic for the null distribution for
comparison to the observed distribution. For continuous
variables, the permutation test was run with the Kruskal-Wallis
test statistic. For categorical variables we used the standard chi-
square statistic for testing association between two categorical
variables.
Locus-by-locus analysis. Associations between covariates
and methylation at individual CpG loci were tested with a
generalized linear model. The b-distribution of average b values
was accounted for with a quasi-binomial logit link with an
estimated scale parameter constraining the mean between 0 and 1,
in a manner similar to that described by Hsuing et al. [43]. Array-
wide scanning for CpG loci associations with sample type or
covariate used false discovery rate estimation and Q-values
computed by the qvalue package in R [44].
Multinomial logistic regression. Multinomial logistic
regression was used to model methylation class while controlling
for potential confounders. Referent class selection does not affect
the underlying interpretation of the model and as class three was
neither the largest, nor the smallest class, and was relatively
hypomethylated it was chosen as the referent class. Because of the
potentially large number of methylation classes, logistic regression
coefficients were regularized using a ridge (L2) penalty, with
coefficients for a common (non-intercept) covariate across
outcome levels shrunk toward zero [34] the tuning parameter
was selected by minimizing Bayesian information criterion.
Sequenom EpiTYPER methylation and RT–PCR. Spear-
man correlation coefficients and test P-values are reported for
correlation between array and Sequenom methylation values.
Tests for association between methylation and mRNA expression
used relative mRNA expression versus array methylation average
b stratified into two groups around 0.5 with the Kruskal-Wallis test
statistic.
Supporting Information
Figure S1 GSTM2 expression is significantly reduced in tumors
with GSTM2 methylation. Relative mRNA expression values for
GSTM2 are plotted versus array methylation values for two CpGs
significantly associated with tumor grade stratified at 0.5. Each box
top and bottom edge represents the third and first quartile
expression values respectively; box center line represents the
median relative expression value. (A) A CpG 153 bases 39 of the
GSTM2 transcription start site has significantly reduced mRNA
expression when methylated (P,0.001). (B) A promoter-based CpG
109 bases 59 of the GSTM2 transcription start site has significantly
reduced mRNA expression when methylated (P,0.03).
Found at: doi:10.1371/journal.pgen.1001043.s001 (0.05 MB
DOC)
Figure S2 Recursively partitioned mixture model of CpG
methylation in breast tumors from post menopausal patients.
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sites and rows represent methylation classes. The height of each
row is proportional to the number of observations residing in the
class (total n=117). Blue indicates methylated and yellow indicates
unmethylated. The color of the columns within each class
represents the average methylation of the CpG for that class.
Found at: doi:10.1371/journal.pgen.1001043.s002 (0.06 MB
DOC)
Table S1 Patient demographic, hormonal, dietary, and tumor
characteristics stratified by menopausal status.
Found at: doi:10.1371/journal.pgen.1001043.s003 (0.04 MB
XLS)
Table S2 Summary of results from locus-by-locus CpG
methylation versus covariates.
Found at: doi:10.1371/journal.pgen.1001043.s004 (0.03 MB
XLS)
Table S3 Tumor size, grade, hormone receptor, and ERBB2
status are highly associated with CpG methylation in breast
carcinoma (n=162).
Found at: doi:10.1371/journal.pgen.1001043.s005 (0.12 MB
XLS)
Table S4 Multinomial logistic regression of methylation class
membership (Class 3 is referent) by patient demographic and
tumor characteristics.
Found at: doi:10.1371/journal.pgen.1001043.s006 (0.04 MB
XLS)
Table S5 DNA methylation profiles of post-menopausal pa-
tients’ breast tumors are significantly associated with estrogen
receptor status.
Found at: doi:10.1371/journal.pgen.1001043.s007 (0.03 MB
XLS)
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